C-peptide determination in the choice of treatment in diabetes mellitus

References

• Binder C, Faber O K. Residual beta-cell function and its metabolic consequences. Diabetes 1978; 27(suppl. 1)226–9
   PubMedGoogle Scholar
• Gonan B, Goldman J, Baldwin D, et al. Metabolic control in diabetic patients. Effects of insulin-secretory reserve (measured by plasma C-peptide levels) and circulating insulin-antibodies. Diabetes 1979; 28: 749–53
   PubMed Web of Science ®Google Scholar
• Madsbad S. Prevalence of residual B-cell function and its metabolic consequences in type 1 (insulin-dependent) diabetes. Diabetologia 1983; 24: 141–7
   PubMed Web of Science ®Google Scholar
• Madsbad S, McNair P, Faber O K, Binder C, Christiansen C, Transbøl I. Beta-cell function and metabolic control in insulin-treated diabetics. Acta Endocrinol 1980; 93: 196–200
   PubMedGoogle Scholar
• Beischer W, Kerner W, Rapti's S, Keller L, Beischer B, Pfeiffer E F. Insulin therapy in relation to circulating C-peptide levels. Diabetes 1978; 27(Suppl. 1)235–40
   PubMed Web of Science ®Google Scholar
• Faber O K, Binder C. B-cell function and blood glucose control in insulin-dependent diabetics within the first month of insulin treatment. Dia-betaologia 1977; 13: 263–8
   Google Scholar
• Rendell M, Ross D A, Drew H M, Zarriello J. Endogenous insulin secretion measured by C-peptide in maturity-onset diabetes controllable by diet alone. Arch Intern Med 1981; 141: 1617–22
   PubMedGoogle Scholar
• Taskinen M-R, Groop L. C-peptide and free insulin determinations in type I diabetes; relationships with metabolic control and insulin therapy. Ann Clin Res 1984; 16: 118–27
   PubMedGoogle Scholar
• Heding L G, Munkgaard Rasmussen S. Human C-peptide in normal and diabetic subjects. Diabetologia 1975; 11: 201–6
   PubMed Web of Science ®Google Scholar
• Hoekstra J BL, van Rijn H JM, Erkelens D W, Thijssen J HH. C-pcptide. Diabetes Care 1982; 5: 438–46
   PubMed Web of Science ®Google Scholar
• Johnston D G, Alberti K GMM, Wright R, et al. C-peptide and insulin in liver disease. Diabetes 1978; 27(Suppl. 1)201–6
   PubMedGoogle Scholar
• Regeur L, Faber O K, Binder C. Plasma C-peptide in uraemic patients. Scand J Clin Lab Invest 1978; 38: 771–5
   PubMed Web of Science ®Google Scholar
• Heding L G, Kasperska-Czyzykowa T. C-peptide and proinsulin after oral glucose. Acta Med Scand 1980; 639(Suppl)33–6
   Google Scholar
• Mirel R D, Ginsberg-Fellner F, Horwitz D L, Rayfield E J. C-peptide reserve in insulin-dependent diabetics. Comparative responses to glucose, glucagon and tolbutamide. Diabetologia 1980; 19: 183–8
   PubMed Web of Science ®Google Scholar
• Ludvigsson J. Methodological aspects on C-peptide measurements. Acta Med Scand 1983; 671(Suppl)53–9
   Google Scholar
• Hendriksen C, Faber O K, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 1977; 13: 615–9
   PubMed Web of Science ®Google Scholar
• Zilker T. Bedeutung der C-peptid-bestimmung fur therapie und prognose biem diabetes. Kombinations-therapie Insulin/Sulfonylharnstoff, W Bachmann, H Mehnert. S. Kar-ger AG, Basel 1983; 43–54
   Google Scholar
• Garcia-Webb P, Bonser A, Welborn T A. Correlation between fasting serum C-peptide and B-cell insulin secretory capacity in diabetes melli-tus. Diabetologia 1982; 22: 296
   PubMed Web of Science ®Google Scholar
• Faber O K, Binder C. C-peptide response to glucagon, a test for the residual B-cell function in diabetes mellitus. Diabetes 1977; 26: 605–10
   PubMed Web of Science ®Google Scholar
• Welborn T A, Garcia-Wcbb P, Bonser A M. Basal C-peptide in the discrimination of type I from type II diabetes. Diabetes Care 1981; 4: 161–9
   Web of Science ®Google Scholar
• Rendell M. C-pcptidc levels as a criterion in treatment of maturity-onset diabetes. J Clin En-docrinol Metab 1983; 57: 1198–206
   PubMed Web of Science ®Google Scholar
• Turkington R W, Estkowski A, Link M. Secretion of insulin or connecting peptide. A predictor of insulin dependence in obese ‘diabetics’. Arch Intern Med 1982; 142: 1102–5
   PubMedGoogle Scholar
• Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153–6
   PubMedGoogle Scholar
• Snedecor G W, Cochran W S. Statistical Methods. 6th ed. Ames, Iowa 1971; 179–97
   Google Scholar
• Madsbad S, Faber O K, Binder C, McNair P, Christiansen C, Transbøl I. Prevalence of residual B-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 1978; 27(Suppl 1)262–4
   PubMedGoogle Scholar
• Madsbad S, Krarup T, Regeur L, Faber O K, Binder C. Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol 1980; 95: 359–63
   PubMedGoogle Scholar
• Groop L. Heterogeneity of type II diabetes. A study of clinical, genetic, immunological and metabolic aspects. Helsinki University, Helsinki 1982; 124, Dissertation
   Google Scholar
• Garcia-Webb P, Bonser A, Whiting D. Importance of fasting plasma glucose concentration and obesity in the interpretation of fasting serum C-peptide values. Clin Chim Acta 1982; 118: 323–6
   PubMed Web of Science ®Google Scholar
• Garcia-Webb P, Zimmert P, Bonser A, King H, Bottomley S. Factors affecting lasting serum C-peptide levels in Microensians: comparison with a Caucasoid population. Diabetologia 1984; 27: 23–6
   PubMed Web of Science ®Google Scholar
• Groop L. Laboratoricdiagnostik vid diabetes mellitus. Fin Läkaresällsk Handl 1981; 125: 217–25
   Google Scholar
• Caygill C PJ, Gaines Das R E, Bangham D R. Use of a common standard for comparison of insulin C-peptide measurement by different laboratories. Diabetologia 1980; 18: 197–204
   PubMed Web of Science ®Google Scholar
• Faber O K, Binder C, Markussen J, et al. Characterization of seven C-peptide antisera. Diabetes 1978; 27(Suppl 1)170–7
   PubMed Web of Science ®Google Scholar
• Villaume C, Beck B. C-peptidc comparative radioimmunoassays, a study of three commercial kits. Ann Biol Clin 1983; 41: 269–72
   PubMed Web of Science ®Google Scholar